CoChat

The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index; 88 of the 108 sources its claims cite were checked for support.

Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer

Open access
Matsuoka, Tasuku, Yashiro, Masakazu · 2024 · International Journal of Molecular Sciences

Abstract

Gastric cancer (GC) is one of the most common cancers worldwide. Most patients are diagnosed at the progressive stage of the disease, and current anticancer drug advancements are still lacking. Therefore, it is crucial to find relevant biomarkers with the accurate prediction of prognoses and good predictive accuracy to select appropriate patients with GC. Recent advances in molecular profiling technologies, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics, have enabled the approach of GC biology at multiple levels of omics interaction networks. Systemic biological analyses, such as computational inference of "big data" and advanced bioinformatic approaches, are emerging to identify the key molecular biomarkers of GC, which would benefit targeted therapies. This review summarizes the current status of how bioinformatics analysis contributes to biomarker discovery for prognosis and prediction of therapeutic efficacy in GC based on a search of the medical literature. We highlight emerging individual multi-omics datasets, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics, for validating putative markers. Finally, we discuss the current challenges and future perspectives to integrate multi-omics analysis for improving biomarker implementation. The practical integration of bioinformatics analysis and multi-omics datasets under complementary computational analysis is having a great impact on the search for predictive and prognostic biomarkers and may lead to an important revolution in treatment.

Overview

CoChat Summary

TL;DR

This narrative review summarizes how bioinformatics and single- or multi-omics analyses have been used to identify predictive and prognostic biomarkers in gastric cancer across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and pharmacogenomics. It argues that integrating multi-omics with computational and machine-learning methods may improve patient stratification and therapy selection, but clinical translation still requires validation, standardization, and large trials.

Key findings

  • Across omics layers, many candidate signatures are reported: a six-metastasis-related gene set; 50 DEGs from 375 TCGA GC samples with 10 linked to outcome and macrophage infiltration; 39 prognostic gene signatures with COL1A1, COL1A2, and EGFR each identified three times; an 11-DMS methylation signature; an eight-MDEG signature; 110 differentially expressed miRNAs with a three-miRNA prognostic signature; 18 immune-related lncRNAs; 429 differentially expressed proteins; 24 survival-associated metabolites with 8 independent prognostic metabolites; and a 28-metabolite model with AUROC 0.832 and concordance index 0.83, in which 11 metabolites significantly discriminated prognosis.
  • Pharmacogenomic and therapeutic prediction studies identified a three-gene platinum-response model (ND6, BRMS1, SRXN1) from 23 survival-related genes; in silico TCGA analysis predicted up to 15% of GC samples would benefit from currently approved targeted therapy versus 50% from FDA-approved alternative targeted therapies; proteomic subtypes from 206 pretreatment tumor samples were linked to XELOX, DOS, and anti-HER2 therapy; and four serum metabolites distinguished chemo-sensitive from chemo-resistant tumors with 82.5% sensitivity and specificity.
  • Multi-omics integration remains challenging: TCGA and ACRG molecular classifications exist but clinical use is limited by intricacy, and no alternative marker set has yet outperformed them; a deep-learning autoencoder using RNA-seq, miRNA-seq, and DNA methylation identified two prognostic subgroups and outperformed PCA and similarity network fusion. Three bioinformatics-based GC clinical trials are ongoing (NCT06035250, NCT05319392, NCT05985577) and one is completed (NCT05620537).
  • Microbiome analysis of 128 samples detected 5,450 phylotypes belonging to 19 phyla and 296 genera; enrichment of *Fusobacterium nucleatum* and *Prevotella* I in cancerous tissues was associated with worse survival.

Methods

  • Non-systematic review based on electronic searches of PubMed and Google Scholar using keywords including “gastric cancer”, “bioinformatics analysis”, “multi-omics”, “artificial intelligence”, “machine learning”, “prognosis”, “prediction”, and “biomarker”.
  • Included review articles and guidelines from 2018 to 2023 on bioinformatic approaches to GC genetic, epigenetic, transcriptomic, proteomic, and metabolic processes; only full English articles published within the last ten years were considered. Exclusions were duplicate articles, studies lacking diagnostic outcomes, case reports, correspondence, letters, and non-human research.
  • No primary data collection, systematic quality appraisal, or meta-analysis was performed; the paper summarizes cited studies and tabulated biomarker examples.

Limitations

  • The paper states that this is a non-systematic review and lists obstacles to clinical implementation: need for large phenotypically characterized datasets, high accuracy and reproducibility, difficulty obtaining suitable tissue samples, strict sample preparation requirements, high costs, incompatible data across databases, need to normalize patient characteristics such as age, race, and stage, and validation through comprehensive cohort studies and large-scale clinical trials; data standardization and benchmarking of integration methods are also needed.
  • Evident from the text and tables: many cited biomarker studies rely on public databases and/or small cohorts (e.g., n=18, 31, 37, 48, 65 in some tables), with limited external validation, and no systematic quality appraisal or quantitative synthesis is reported.
  • Evident: as a narrative review, it does not provide new experimental validation and cannot establish the clinical utility of the listed candidate markers.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms25115880

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic diagram of validation of biomarker by the integration of bioinformatic analysis with multi-omics platforms. Different omics technologies and their features, such as omics targeted, sequencing techniques, data processing, data analysis, and output, were displayed. The first step is the identification of high-quality samples obtained by blood, tissue samples from GC patients, or high-throughput datasets. Multi-platform omics technologies are analyzed individually to identify the DNA, RNA, proteins, and metabolites responsible for the GC progression. Omics data are extracted by the search for various omics databases, mining of the data, and obtaining the pre-processed omics data. Thereby, data are transformed and processed through normalization, quality control, and feature selection to mine interpretable information. These multidimensional data can be integrated based on statistical analysis, machine learning, and functional analysis, which lead to the discovery of putative biomarkers.
Figure 1 Schematic diagram of validation of biomarker by the integration of bioinformatic analysis with multi-omics platforms. Different omics technologies and their features, such as omics targeted, sequencing techniques, data processing, data analysis, and output, were displayed. The first step is the identification of high-quality samples obtained by blood, tissue samples from GC patients, or high-throughput datasets. Multi-platform omics technologies are analyzed individually to identify the DNA, RNA, proteins, and metabolites responsible for the GC progression. Omics data are extracted by the search for various omics databases, mining of the data, and obtaining the pre-processed omics data. Thereby, data are transformed and processed through normalization, quality control, and feature selection to mine interpretable information. These multidimensional data can be integrated based on statistical analysis, machine learning, and functional analysis, which lead to the discovery of putative biomarkers.CC BY · PubMed Central

Verification

Claims the paper makes

81 Valid · 4 Not valid · 12 Not checked · 12 Own results and interpretations

48 more claims · 41 with their cited sources checked

Create a free account to see all 109 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 38

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 117 references

Cited by

See all 83

Metadata

Authors
Matsuoka, T., & Yashiro, M.
Affiliations
Osaka Metropolitan University (JP)
Corresponding author
Yashiro, Masakazu
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-05-28
Volume
25
Issue
11
Pages
5880
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4399084028
Cited by
83
References
119
Citations by year
2026: 29 · 2025: 51 · 2024: 3
FWCI
6.11
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
KAKENHI (Grant-in-Aid for Scientific Research) (21H03008)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
Keywords
gastric cancer, prognostic factors, predictive biomarkers, multi-omics integration, epigenomics, transcriptomics, proteomics, metabolomics, genomics, biomarker discovery, therapeutic efficacy prediction, targeted therapy
MeSH terms
Humans, Prognosis, Stomach Neoplasms, Biomarkers, Tumor, Computational Biology, Genomics, Proteomics, Metabolomics, Epigenomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer. https://app.cochat.ai/papers/10.3390/ijms25115880
The paper
Matsuoka, T., & Yashiro, M. (2024). Bioinformatics Analysis and Validation of Potential Markers Associated with Prediction and Prognosis of Gastric Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115880

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.